Skip to main content
  • Scientific Core Facilities Fueling Cancer Center’s Success

    Kevin Cullen, M.D., Director, Marlene and Stewart Greenebaum Comprehensive Cancer Center discusses the important role the Center for Innovative Biomedical Resources (CIBR) have played in the Cancer Center’s success.

    Watch the Video

Translational Laboratory Shared Service

Watch a video about the Translational Laboratory Shared Service >>

The University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) Translational Shared Service (TLSS) offers pre-clinical and clinical experimental support to basic researchers and physicians in the UMGCC community. We work in areas across the entire spectrum: cell biology, in vitro, in vivo and human trials. 

In Vitro Assays 

  • IC50 generation
  • Cell cycle (propidium iodide)
  • Viability (trypan blue exclusion)
  • Apoptosis
  • Potentiation/Synergy
  • ROS
  • Western Analysis
  • Angiogenesis
  • Mycoplasma testing


  • Real time proliferation/invasion/migration

In Vivo Assays 

  • IACUC approved umbrella protocol
  • Tolerability:
  • Tumor Growth
  • Pharmacokinetics: generation of plasma
  • Efficacy (flank models)
  • Efficacy (orthotopic models)
  • Pharmacodynamic Endpoints
  • Imaging of cells with Xenogen System

Clinical Trial Support 

We isolate:

  • Plasma
  • Serum
  • Tumor Biopsy
  • Whole Blood (isolation of PBMC,
  • DNA, RNA, protein)
  • Bone Marrow (isolation of marrow
  • Buccal Mucosa

Pharmacodynamic (PD) Endpoints 

  • in patient samples, tumor or surrogate tissues, preclinical samples
  • endpoint dependent on target (e.g., ELISA, flow cytometry, Western, unique assay)

renaRena Lapidus, Ph.D.

Room 7-010, Bressler Research Building
655 West Baltimore Street
Baltimore, MD 21201

Services We Offer

  • Access to 50+ human cell lines
  • Luciferase-expressing breasts and prostate cancer cell lines
  • IACUC approved umbrella protocol
  • Access/ knowledge in using Xenogen/ IVIS image mice
  • Primary Xenograft Models
    • Breast
    • Leukemia (under development)
    • Ovarian (under development)
  • Access to IRB approved protocol for tissue acquisition

Get pricing & info